Form 4: Wave Life Sciences Director Sells 30,000 Shares Under Pre-Arranged Trading Plan

Gregory L. Verdine, a Director at Wave Life Sciences Ltd., sold 30,000 ordinary shares for approximately $6.95 per share on June 13, 2025, as part of a Rule 10b5-1 trading plan.

Summary

• Gregory L. Verdine, a Director of Wave Life Sciences Ltd. (WVE), reported a sale of ordinary shares.
• The transaction involved the disposition of 30,000 ordinary shares.
• The sale occurred on June 13, 2025.
• The weighted-average sale price for the shares was $6.95, with individual transactions ranging from $6.79 to $7.04 per share.
• Following this transaction, Mr. Verdine beneficially owns 282,517 ordinary shares directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Verdine on March 13, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, but mitigated by the fact it was a pre-planned sale under a Rule 10b5-1 plan, which suggests it's for personal financial management rather than a reaction to negative company news.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction for diversification or liquidity rather than a reaction to new negative company developments.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence, although this is mitigated by the pre-planned nature of the sale.

Future Outlook

NA

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

This filing is specific to an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May view the insider sale with caution, though the 10b5-1 plan mitigates concerns about a lack of confidence in the company's future.

Key Dates

Keywords

Wave Life Sciences, WVE, SEC Form 4, Insider Trading, Stock Sale, Director, Gregory L. Verdine, Rule 10b5-1, Beneficial Ownership